Comparing treatment effects of intensification with IC50 and HM50 at 12 months
| IC50 | HM50 | Difference in mean change (95% CI) | |||||
|---|---|---|---|---|---|---|---|
| n (%) | Mean change (SD) | 95% CI | n (%) | Mean change (SD) | 95% CI | ||
| Outcome | |||||||
| Responders | 184 (32) | −1.91 (1.1) | (−2.07 to −1.75) | 273 (40) | −1.97 (1.0) | (−2.09 to −1.86) | 0.07 (−0.13 to 0.26) |
| Non-responders | 399 (68) | 0.34 (1.1) | (0.23 to 0.45) | 411 (60) | 0.26 (0.9) | (0.17 to 0.35) | 0.08 (−0.06 to 0.22) |
| HbA1c (%) (mmol/mol) | 583 (46) | −0.37 (1.5) −4.00 (16.4) | (−0.49 to −0.25) (−5.40 to −2.70) | 684 (54) | −0.63 (1.5) −6.90 (16.4) | (−0.74 to −0.52) (−8.10 to −5.7) | −0.26 (−0.43 to −0.10) −2.80 (−4.70 to −1.10) |
| HbA1c subgroups (%) (mmol/mol) | |||||||
| HbA1c (<8%) (<64) | 84 (14) | 0.57 (1.3) 6.20 (14.2) | (0.28 to 0.85) (3.10 to 9.3) | 41 (6) | 0.09 (1.0) 1.00 (10.9) | (−0.23 to 0.41) (−2.50 to 4.50) | 0.48 (0.02 to 0.94) 5.20 (0.20 to 10.3) |
| HbA1c (8 to <9%) (64 to <75) | 177 (30) | −0.05 (1.5) −0.50 (16.4) | (−0.27 to 0.17) (−3.00 to 1.90) | 190 (28) | 0.01 (1.2) 0.10 (13.1) | (−0.16 to 0.17) (−1.7 to 1.9) | −0.06 (−0.34 to 0.22) −0.720 (−3.70 to 2.40) |
| HbA1c (≥9%) (≥75) | 322 (55) | −0.79 (1.5) −8.60 (16.4) | (−0.95 to −0.63) (−10.40 to −6.9) | 453 (66) | −0.97 (1.5) −10.60 (18) | (−1.11 to −0.83) (−12.1 to −9.10) | 0.18 (−0.03 to 0.39) 2.00 (−0.30 to 4.30) |
| Weight (kg) | 0.94 (4.9) | (0.54 to 1.34) | 0.87 (6.5) | (0.38 to 1.36) | 0.07 (−0.58 to 0.71) | ||
HbA1c; glycated hemoglobin; HM50, Humalog Mix50; IC50, Insuman Comb 50.